中国生物制药TQB3454 IDH1抑制剂针对胆道癌III期临床试验获积极结果

美股速递
Mar 12

中国生物制药宣布,其研发的TQB3454 IDH1抑制剂在针对胆道癌的III期临床试验中取得积极成果。该研究达到主要终点,显示药物可显著延长患者无进展生存期,且安全性与耐受性良好。

此次突破为胆道癌患者提供了新的治疗选择,标志着公司在创新药研发领域的重要进展。TQB3454作为口服靶向药物,通过抑制IDH1突变蛋白活性发挥抗肿瘤作用。

公司计划基于该数据向国家药品监督管理局提交上市申请,若获批将成为国内首个针对胆道癌的IDH1抑制剂。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10